Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone

Phase 3 Not yet recruiting 69 enrolled New York Medical College

RandomizedCrossoverOpen-labelTreatment

Summary

Patients with refractory ADV or CMV infection post allogeneic stem cell transplant will be randomized to either Family donor-derived viral specific cytotoxic T lymphocytes (CTLs) plus standard of care (SOC) vs SOC alone.

Timeline

Start: 2026-12-01
Primary completion: 2031-12-01
Completion: 2032-12-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cytotoxic T Lymphocytes	Cell therapy	—	—

Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone

Summary

Timeline

Drugs

Indications